Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis

Pediatric Blood and Cancer

Volumn 53, Issue 2, 2009, Pages 162-167

  Kearney, Susan L ^a,f   Dahlberg, Suzanne E ^b   Levy, Donna E ^c   Voss, Stephan D ^d,e   Sallan, Stephen E ^d,e   Silverman, Lewis B ^d,e  

^a UNIVERSITY OF MINNESOTA   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c RHO INC   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e BOSTON CHILDREN S HOSPITAL   (United States)

^f NONE   (United States)

Author keywords

Asparaginase; Leukemia; Pancreatitis

Indexed keywords

AMYLASE; ASPARAGINASE; MACROGOL; NARCOTIC AGENT; TRIACYLGLYCEROL LIPASE; ANTINEOPLASTIC AGENT;

ABDOMINAL PAIN; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AMYLASE BLOOD LEVEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURGERY; CHILD; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE COURSE; DRUG MEGADOSE; ECHOGRAPHY; ERWINIA; ESCHERICHIA COLI; EVENT FREE SURVIVAL; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; OUTCOME ASSESSMENT; PANCREATITIS; PANCREATOGRAPHY; PARENTERAL NUTRITION; PRESCHOOL CHILD; PRIORITY JOURNAL; REPEATED DRUG DOSE; RETROSPECTIVE STUDY; SCHOOL CHILD; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; INFANT; MULTICENTER STUDY; NEWBORN; PROGNOSIS; TUMOR RECURRENCE;

ADOLESCENT; ANTINEOPLASTIC AGENTS; ASPARAGINASE; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; HUMANS; INFANT; INFANT, NEWBORN; NEOPLASM RECURRENCE, LOCAL; PANCREATITIS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; TREATMENT OUTCOME;

EID: 67649968213     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22076     Document Type: Article

References (29)

1. Broome JD. Studies on the mechanism of tumor inhibition by L-asparaginase. Effects of the enzyme on asparagine levels in the blood, normal tissues, and 6C3HED lymphomas of mice: Differences in asparagine formation and utilization in asparaginase-sensitive and -resistant lymphoma cells. J Exp Med 1968;127(6): 1055-1072.
2. Horowitz B, Madras BK, Meister A, et al. Asparagine synthetase activity of mouse leukemias. Science (New York, NY) 1968; 160(827):533-535.
3. Haskell CM, Canellos GP. l-asparaginase resistance in human leukemia-asparagine synthetase. Biochem Pharmacol 1969; 18(10):2578-2580.
4. Tallal L, Tan C, Oettgen H, et al. E. coli L-asparaginase in the treatment of leukemia and solid tumors in 131 children. Cancer 1970;25(2):306-320.
5. Rausen A. L-Asparaginase (L-ASP) in advanced childhood leukemia: Comparative trial of drug schedules singly and in combination. Proc Am Assn Cancer Res 1970;137-144.
6. Jones B, Holland JF, Glidewell O, et al. Optimal use of L-asparaginase (NSC-109229) in acute lymphocytic leukemia. Med Pediatr Oncol 1977;3(4):387-400. (Pubitemid 8235411)
7. Sallan SE, Hitchcock-Bryan S, Gelber R, et al. Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia. Cancer Res 1983;43(11):5601-5607. (Pubitemid 14230187)
8. Clavell LA, Gelber RD, Cohen HJ, et al. Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. N Engl J Med 1986;315(11):657-663.
9. LeClerc JM, Billett AL, Gelber RD, et al. Treatment of childhood acute lymphoblastic leukemia: Results of Dana-Farber ALL Consortium Protocol 87-01. J Clin Oncol 2002;20(1):237-246. (Pubitemid 34032617)
10. Schorin MA, Blattner S, Gelber RD, et al. Treatment of childhood acute lymphoblastic leukemia: Results of Dana-Farber Cancer Institute/Children's Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01. J Clin Oncol 1994;12(4):740-747. (Pubitemid 24110913)
11. Silverman LB, Declerck L, Gelber RD, et al. Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981-1995). Leukemia 2000;14(12):2247-2256.
12. Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: Results of Dana-Farber Consortium Protocol 91-01. Blood 2001;97(5):1211-1218. (Pubitemid 32183741)
13. Moghrabi A, Levy DE, Asselin B, et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-0 for children with acute lymphoblastic leukemia. Blood 2007;109(3):896-904. (Pubitemid 46220632)
14. Haskell CM, Canellos GP, Leventhal BG, et al. L-asparaginase: Therapeutic and toxic effects in patients with neoplastic disease. N Engl J Med 1969;281(19):1028-1034.
15. Jaffe N, Traggis D, Das L, et al. L-asparaginase in the treatment of neoplastic diseases in children. Cancer Res 1971;31(7):942-949.
16. Nesbit M, Chard R, Evans A, et al. Evaluation of intramuscular versus intravenous administration of L-asparaginase in childhood leukemia. Am J Pediatr Hematol Oncol 1979;1(1):9-13. (Pubitemid 11198758)
17. Alvarez OA, Zimmerman G. Pegaspargase-induced pancreatitis. Med Pediatr Oncol 2000;34(3):200-205.
18. Weetman RM, Baehner RL. Latent onset of clinical pancreatitis in children receiving L-asparaginase therapy. Cancer 1974;34(3): 780-785.
19. Knoderer HM, Robarge J, Flockhart DA. Predicting asparaginase-associated pancreatitis. Pediatr Blood Cancer 2007;49(5):634-639.
20. Gugliotta L, D'Angelo A, Mattioli Belmonte M, et al. Hypercoagulability during L-asparaginase treatment: The effect of antithrombin III supplementation in vivo. Br J Haematol 1990; 74(4):465-470. (Pubitemid 20122748)
21. Gugliotta L, Mazzucconi MG, Leone G, et al. Incidence of thrombotic complications in adult patients with acute lymphoblastic leukaemia receiving L-asparaginase during induction therapy: A retrospective study. GIMEMA Group Eur J Haematol 1992;49(2):63-66.
22. Leone G, Gugliotta L, Mazzucconi MG, et al. Evidence of a hypercoagulable state in patients with acute lymphoblastic leukemia treated with low dose of E. coli L-asparaginase: A GIMEMA study. Thromb Haemost 1993;69(1):12-15. (Pubitemid 23026189)
23. Avramis VI, Sencer S, Periclou AP, et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: A Children's Cancer Group study. Blood 2002;99(6):1986-1994. (Pubitemid 34525479)
24. Duval M, Suciu S, Ferster A, et al. Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: Results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial. Blood 2002;99(8):2734-2739. (Pubitemid 34525359)
25. Jaffe N. Diabetes mellitus secondary to L-asparaginase therapy. J Pediatr 1972;81(6):1220-1221.
26. Land VJ, Sutow WW, Fernbach DJ, et al. Toxicity of L-asparginase in children with advanced leukemia. Cancer 1972;30(2):339-347.
27. Sutow WW, George S, Lowman JT, et al. Evaluation of dose and schedule of L-asparaginase in multidrug therapy of childhood leukemia. Med Pediatr Oncol 1976;2(4):387-395. (Pubitemid 8011689)
28. Parsons SK, Skapek SX, Neufeld EJ, et al. Asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia. Blood 1997;89(6):1886-1895. (Pubitemid 27132102)
29. Weinstein JN. Searching for pharmacogenomic markers: The synergy between omic and hypothesis-driven research. Dis Markers 2001;17(2):77-88.